Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT03064867
Active Not Recruiting
The purpose of this study is to determine the correct dose and safety of adding a new cancer drug, venetoclax, to a standard combination of chemotherapy drugs as a second treatment for relapsed/refractory DLBCL. In this study, venetoclax will be added to RICE (rituximab, ifosfamide, carboplatin, etoposide), a common set to cancer drugs used as a second line treatment for relapsed/refractory DLBCL. Venetoclax, is a new targeted anti-cancer drug, which works by mimicking a particular protein prod... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2022
Locations: Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri +2 locations
Conditions: Diffuse Large B-cell-lymphoma
Register for Updates
SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
NCT05093387
Withdrawn
This phase I trial studies the effect of SGT-53, carboplatin, and pembrolizumab in treating patients with triple negative inflammatory breast that has spread to other parts of the body (metastatic). SGT-53 is a gene therapy that changes the deoxyribonucleic acid (DNA) of patients' tumor cells to make it easier for the immune system to recognize them. SGT-53 targets the TP53 gene, which is frequently mutated in IBC cells. Chemotherapy drugs, such as carboplatin, work in different ways to stop the... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Northwestern University, Chicago, Illinois
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Register for Updates
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
NCT02703272
Terminated
The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival \[EFS\]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone (part 2).
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/07/2022
Locations: Not set, Los Angeles, California +76 locations
Conditions: Lymphoma, Non-Hodgkin
Register for Updates
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
NCT05245760
Withdrawn
This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/04/2022
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Esophageal Cancer, Esophagogastric Junction Cancer
Register for Updates
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
NCT01779050
Terminated
This phase II trial studies the efficacy of trastuzumab treatment in breast cancer patients with stage II-III human epidermal growth factor receptor 2 (HER2)-negative tumors and HER2-expressing bone marrow disseminated tumor cells (DTCs). Administering targeted trastuzumab therapy to these patients may result in the elimination of HER2 expressing disseminated tumor cells and improved disease free survival.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/31/2022
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Neoplasms
Register for Updates
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
NCT01649947
Completed
The purpose of this study is to examine the combination of one standard treatment for lung cancer plus an additional drug, hydroxychloroquine. The standard treatment for lung cancer being used includes 2 chemotherapy drugs, called paclitaxel and carboplatin. Some patients who have a specific type of lung cancer can also receive another drug, a drug that targets blood vessels, called bevacizumab (also known as avastin). Hydroxychloroquine is an FDA approved drug for the treatment of malaria, rheu... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/28/2022
Locations: Robert Wood Johnson University Hospital at Hamilton, Hamilton, New Jersey +1 locations
Conditions: Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Register for Updates
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
NCT01795586
Completed
This study is being done to see how safe the combination of eribulin and carboplatin is and if it will work to help people with advanced breast cancer. Eribulin and carboplatin are both chemotherapy drugs. They work by killing cancer cells. A person is made up of cells which control every function in the body. Some cells stop working like they should and become cancer cells. These cancer cells grow and multiply rapidly and can cause destruction to normal body organs. Eribulin and carboplatin hav... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/28/2022
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Breast Cancer
Register for Updates
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
NCT01414608
Completed
This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of \[cancer/tumor\] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Exte... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/27/2022
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +325 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Register for Updates
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
NCT02598895
Completed
This pilot clinical trial studies docetaxel and carboplatin in treating patients with castration resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic) and contains inactivated genes in the BRCA 1/2 pathway. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer
Register for Updates
Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
NCT01088802
Completed
This research is being done to try to reduce radiation side effects that happen with the standard radiation methods. Generally surgery, radiation therapy, and sometimes chemotherapy are standard treatment for people with squamous cell carcinoma of the oropharynx. The study will look at giving a slightly smaller dose of radiation (de-intensification) to see if regularly expected late toxicities (two years after receiving treatment) can be reduced. This study will also try to see if the smaller d... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
10/14/2022
Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Squamous Cell Carcinoma of Oropharynx
Register for Updates
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
NCT02124902
Terminated
This is a single arm open label phase II study in women with clinical stage 2 or 3 triple negative breast cancer to assess the anti-tumor activity (in terms of pathologic complete response rate) of neoadjuvant docetaxel in combination with carboplatin. Patient derived xenografts will also be developed simultaneously for the purposes of genoproteomic analysis. Please note that Baylor College of Medicine (BCM) has a parallel study the same as this study. Baylor is expected to enroll approximately... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/12/2022
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Triple Negative Breast Neoplasms
Register for Updates
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
NCT04022876
Terminated
This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line treatment with topotecan. (Part 1 has completed enrollment). Part 2 NSCLC is a randomized, double-blind, placebo-controlled, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2022
Locations: Arizona Cancer Center, Kingman, Arizona +27 locations
Conditions: Non Small Cell Lung Cancer, Small-cell Lung Cancer
Register for Updates